DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
HASBROUCK HEIGHTS, N.J., May 10, 2017 -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) will hold a teleconference call for shareholders today May 10 at 4:30 EDT. The call in number is 1-888-424-8151 and the passcode is 7826703# (for Canada please use 1-888-465-5079).
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports.
Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com
